SyntheticMR Valuation
Is SYNT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SYNT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SYNT (SEK27.7) is trading below our estimate of fair value (SEK42.22)
Significantly Below Fair Value: SYNT is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SYNT?
Key metric: As SYNT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is SYNT's PE Ratio? | |
|---|---|
| PE Ratio | 115.3x |
| Earnings | SEK 10.01m |
| Market Cap | SEK 1.15b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 12x |
| Enterprise Value/EBITDA | 78.6x |
| PEG Ratio | 2.4x |
Price to Earnings Ratio vs Peers
How does SYNT's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 66x | ||
RAY B RaySearch Laboratories | 44x | 26.2% | SEK 6.4b |
PTRK Physitrack | 4.5x | n/a | SEK 130.1m |
KONT Kontigo Care | 93x | 99.6% | SEK 103.8m |
SECT B Sectra | 122.7x | 21.2% | SEK 54.9b |
SYNT SyntheticMR | 115.3x | 47.4% | SEK 1.2b |
Price-To-Earnings vs Peers: SYNT is expensive based on its Price-To-Earnings Ratio (115.3x) compared to the peer average (53.2x).
Price to Earnings Ratio vs Industry
How does SYNT's PE Ratio compare vs other companies in the European Healthcare Services Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: SYNT is expensive based on its Price-To-Earnings Ratio (115.3x) compared to the European Healthcare Services industry average (26.3x).
Price to Earnings Ratio vs Fair Ratio
What is SYNT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 115.3x |
| Fair PE Ratio | 46.5x |
Price-To-Earnings vs Fair Ratio: SYNT is expensive based on its Price-To-Earnings Ratio (115.3x) compared to the estimated Fair Price-To-Earnings Ratio (46.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Iconovo
SEK 78.6m
Develops and licenses inhalation medications in Sweden.
ICO
SEK 5.10
7D
-1.2%
1Y
-46.3%
Dignitana
SEK 92.6m
A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.
DIGN
SEK 1.10
7D
-4.3%
1Y
-48.6%
Mentice
SEK 544.6m
Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.
MNTC
SEK 21.00
7D
-16.0%
1Y
-52.3%